MADRID, Spain—A novel patch-pump capable of delivering subcutaneous furosemide over a 5-hour period results in similar bioavailability and efficacy as an intravenous infusion and is well tolerated by ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure. Last year, the drug developer noted that FDA feedback from a 2023 Type D ...

Hikma has launched furosemide injection, in 20mg/2ml, 40mg/4ml, 100mg/10ml, 500mg/50ml and 1,000mg/100ml presentations. “Hikma is introducing the first FDA approved 50ml and 100ml presentations to the ...

A Prescription Drug User Fee Act target date of July 26, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the ...

Furosemide injection is a diuretic indicated for parenteral therapy for patients unable to take oral medications or for patients in emergency clinical situations. Meitheal Pharma is offering ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end ...